USMAN NASSIM 4

4 · GYRE THERAPEUTICS, INC. · Filed May 2, 2024

Form 4

Period: 2024-05-01

DirectorPresident & CEO

Transactions

Sale
Common Stock
2024-05-01$14.90/sh−5,000$74,500→ 1,736 total
Sale
Common Stock
2024-05-01$15.63/sh−100$1,563→ 1,636 total
Exercise/Conversion
Common Stock
2024-05-01$6.93/sh+20,000$138,600→ 21,636 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-05-01−20,000→ 281,652 total
Exercise: $6.93Exp: 2033-10-31→ Common Stock (20,000 underlying)
Sale
Common Stock
2024-05-01$13.86/sh−14,900$206,514→ 6,736 total

Holdings

Footnotes (4)

[F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023.
[F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $13.50 to $14.44. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
[F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.32. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
[F4]This option is vested in full.

Documents

1 file